Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$13.44 USD
-0.39 (-2.82%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $13.43 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DNLI 13.44 -0.39(-2.82%)
Will DNLI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNLI
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Other News for DNLI
Denali Therapeutics' CMO Joins Royalty Pharma Board | DNLI Stock News
Royalty Pharma appoints Ho, Weatherman to board of directors
Denali noted no FDA panel meeting in call with William Blair
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License ...
Denali Therapeutics Inc (DNLI) Announces FDA Priority Review for Tividenofusp Alfa | DNLI stock news